Drucebo effect - the challenge we should all definitely face!
作者信息
Banach Maciej, Penson Peter E
机构信息
Department of Hypertension, Medical University of Lodz (MUL), Lodz, Poland.
Liverpool John Moores University, Liverpool, UK.
出版信息
Arch Med Sci. 2021 Jan 12;17(2):542-543. doi: 10.5114/aoms/132304. eCollection 2021.
Abstract
摘要
相似文献
1
Drucebo effect - the challenge we should all definitely face!安慰剂效应——我们都绝对应该面对的挑战！
Arch Med Sci. 2021 Jan 12;17(2):542-543. doi: 10.5114/aoms/132304. eCollection 2021.
2
Response to "Drucebo effect - the challenge we should all definitely face!".对《反安慰剂效应——我们都绝对应该面对的挑战！》的回应
Arch Med Sci. 2021 Feb 26;17(2):544-545. doi: 10.5114/aoms/132884. eCollection 2021.
3
Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.引入他汀类药物治疗中的“Drucebo 效应”：一项系统评价比较了在盲法和开放标签条件下报告的他汀类药物相关肌肉症状发生率的研究。
J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023-1033. doi: 10.1002/jcsm.12344. Epub 2018 Oct 11.
4
"Integrating the Drucebo Effect Into PM&R: Enhancing Outcomes Through Expectation Management".将安慰剂效应融入物理医学与康复：通过期望管理改善治疗效果
Am J Phys Med Rehabil. 2024 Nov 1;103(11):e174. doi: 10.1097/PHM.0000000000002544. Epub 2024 May 9.
5
Can we further optimize statin therapy to increase tolerability?我们能否进一步优化他汀类药物治疗以提高耐受性？
Expert Opin Drug Discov. 2019 Sep;14(9):843-847. doi: 10.1080/17460441.2019.1615436. Epub 2019 May 17.
6
The Relationship Between Circulating Acetaminophen-Protein Adduct Concentrations and Alanine Aminotransferase Activities in Patients With and Without Acetaminophen Overdose and Toxicity.在有和没有对乙酰氨基酚过量和中毒的患者中，循环乙酰氨基酚-蛋白加合物浓度与丙氨酸氨基转移酶活性之间的关系。
J Med Toxicol. 2019 Jul;15(3):143-155. doi: 10.1007/s13181-019-00705-2. Epub 2019 Apr 12.
7
An event-related brain potential study of explicit face recognition.一项关于外显面孔识别的事件相关脑电位研究。
Neuropsychologia. 2011 Jul;49(9):2736-45. doi: 10.1016/j.neuropsychologia.2011.05.025. Epub 2011 Jun 6.
8
Attitudes of Danish doctors and nurses to palliative and terminal care.丹麦医生和护士对姑息治疗和临终关怀的态度。
Palliat Med. 2005 Mar;19(2):119-27. doi: 10.1191/0269216305pm988oa.
9
Predictive value of definitely abnormal general movements in the general population.正常人群中明确异常的一般性运动的预测价值。
Dev Med Child Neurol. 2010 May;52(5):456-61. doi: 10.1111/j.1469-8749.2009.03529.x. Epub 2009 Nov 30.
10
Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.小鼠实验性念珠菌病、隐球菌病和曲霉病的联合治疗
Chemotherapy. 1982;28(6):461-79. doi: 10.1159/000238138.
引用本文的文献
1
Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association.波兰专家小组关于匹伐他汀在波兰治疗血脂异常中应用的立场文件，经波兰脂质协会认可。
Arch Med Sci. 2023 Nov 26;20(1):28-42. doi: 10.5114/aoms/175879. eCollection 2024.
2
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?2023年：心血管疾病之年——新型及前瞻性降脂疗法之年。到2024年我们能让血脂异常成为罕见病吗？
Arch Med Sci. 2023 Nov 2;19(6):1602-1615. doi: 10.5114/aoms/174743. eCollection 2023.
3
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia.沙特阿拉伯急性冠状动脉综合征患者血脂管理的前瞻性评估。
Saudi Med J. 2023 Jun;44(6):570-579. doi: 10.15537/smj.2023.44.6.20230023.
4
2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.2022年：心血管疾病之年——起始联合降脂治疗之年
Arch Med Sci. 2022 Nov 7;18(6):1429-1434. doi: 10.5114/aoms/156147. eCollection 2022.
5
Statin Intolerance-We Know Everything, We Know Nothing.他汀不耐受——我们自以为无所不知，实则一无所知。
J Clin Med. 2022 Sep 5;11(17):5250. doi: 10.3390/jcm11175250.
6
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).逐步诊断和管理他汀类药物相关肌肉症状患者的安慰剂/反安慰剂效应：国际脂质专家组（ILEP）的立场文件。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.
7
Prevalence of statin intolerance: a meta-analysis.他汀类药物不耐受的流行率：一项荟萃分析。
Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.
8
CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities.CRISPR基因编辑在脂质紊乱和动脉粥样硬化中的作用：机制与机遇
Metabolites. 2021 Dec 9;11(12):857. doi: 10.3390/metabo11120857.
9
Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice.营养保健品在临床实践中控制血脂异常的应用。
Nutrients. 2021 Aug 25;13(9):2957. doi: 10.3390/nu13092957.
10
RNA Silencing in the Management of Dyslipidemias.RNA沉默在血脂异常管理中的应用
Curr Atheroscler Rep. 2021 Sep 1;23(11):69. doi: 10.1007/s11883-021-00968-7.
本文引用的文献
1
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.在二级预防中，LDL 胆固醇应该降低多少？PCSK9 抑制剂时代的临床疗效和安全性。
Prog Cardiovasc Dis. 2021 Jul-Aug;67:65-74. doi: 10.1016/j.pcad.2020.12.008. Epub 2020 Dec 28.
2
Statins and LDL-C in Secondary Prevention-So Much Progress, So Far to Go.他汀类药物与低密度脂蛋白胆固醇在二级预防中的应用——虽已取得诸多进展，但仍任重道远。
JAMA Netw Open. 2020 Nov 2;3(11):e2025675. doi: 10.1001/jamanetworkopen.2020.25675.
3
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.一项比较他汀类药物、安慰剂或不治疗以评估副作用的单病例试验。
N Engl J Med. 2020 Nov 26;383(22):2182-2184. doi: 10.1056/NEJMc2031173. Epub 2020 Nov 15.
4
An overview of statin-induced myopathy and perspectives for the future.他汀类药物所致肌病概述及未来展望
Expert Opin Drug Saf. 2020 May;19(5):601-615. doi: 10.1080/14740338.2020.1747431. Epub 2020 Apr 13.
5
Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.引入他汀类药物治疗中的“Drucebo 效应”：一项系统评价比较了在盲法和开放标签条件下报告的他汀类药物相关肌肉症状发生率的研究。
J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023-1033. doi: 10.1002/jcsm.12344. Epub 2018 Oct 11.
6
Statin Intolerance: Some Practical Hints.他汀不耐受：一些实用提示。
Cardiol Clin. 2018 May;36(2):225-231. doi: 10.1016/j.ccl.2017.12.004. Epub 2018 Feb 21.
7
Management of Statin Intolerance in 2018: Still More Questions Than Answers.2018 年他汀类药物不耐受的管理：仍有许多问题有待解答。
Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173. doi: 10.1007/s40256-017-0259-7.
8
Optimizing Cholesterol Treatment in Patients With Muscle Complaints.优化有肌肉不适症状患者的胆固醇治疗。
J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752.
9
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.在 Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm（ASCOT-LLA）中，与未设盲、但与设盲他汀类药物治疗相关的不良事件：一项随机、双盲、安慰剂对照试验及其非随机、非盲扩展阶段。
Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2.
10
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.他汀类药物不耐受与心肌梗死后冠心病事件和全因死亡率的关系。
J Am Coll Cardiol. 2017 Mar 21;69(11):1386-1395. doi: 10.1016/j.jacc.2016.12.036.
Zotero 插件